Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CYTOMEL vs CHOLOXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.
Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.
Primary hypothyroidism (as replacement therapy),Thyroid-stimulating hormone (TSH) suppression in thyroid cancer,Myxedema coma (off-label),Nontoxic goiter (off-label)
FDA-approved: Adjunctive therapy in euthyroid patients with primary hypercholesterolemia (elevated LDL) who have not responded to diet and other measures.,Off-label: Treatment of hypothyroidism (though not preferred); investigational use for reducing cardiovascular risk.
Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.
50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.
The terminal elimination half-life of liothyronine is approximately 1.0-2.5 days in euthyroid individuals, but may be prolonged in hypothyroidism (up to 3-4 days) and shortened in hyperthyroidism. Clinical context: This short half-life allows rapid dose titration and withdrawal for thyroid suppression tests.
Terminal elimination half-life is approximately 1-2 hours in euthyroid patients; may be prolonged in hypothyroidism or hepatic impairment.
Primarily hepatic conjugation (glucuronidation and sulfation) and minor deiodination; not extensively metabolized by cytochrome P450.
Primarily hepatic; undergoes deiodination and conjugation to glucuronides and sulfates. Hepatic clearance involves CYP450 enzymes, with a half-life of approximately 12-24 hours.
Liothyronine (T3) is primarily eliminated by hepatic metabolism (deiodination and conjugation). Approximately 50-60% of a dose is excreted in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 20-30% via biliary elimination of conjugates.
Primarily renal excretion of conjugated metabolites (70-80% of dose); biliary/fecal excretion accounts for 10-20%; less than 5% excreted unchanged.
99.7% bound to plasma proteins, primarily thyroxine-binding globulin (TBG) (80%), transthyretin (10%), and albumin (10%).
Highly bound (>99%) to thyroxine-binding globulin (TBG), transthyretin, and albumin.
Volume of distribution is approximately 0.4-0.6 L/kg, indicating distribution into total body water. Clinical meaning: Vd is lower than for T4 due to higher protein binding; rapid distribution into tissues occurs.
Apparent volume of distribution is 0.10-0.20 L/kg, reflecting extensive tissue binding and distribution.
Oral bioavailability is approximately 95% (range 90-100%) when taken on an empty stomach; food may slightly reduce absorption. Intravenous bioavailability is 100%.
Oral bioavailability is 50-80%, reduced by food, bile acid sequestrants, and certain drugs.
No specific dose adjustment required for renal impairment.
No dose adjustment required for renal impairment as drug is hepatically cleared.
No specific dose adjustment required for hepatic impairment; monitor thyroid function closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 25-50%. Child-Pugh C: reduce dose by 50-75% and monitor T4 closely.
Initial 5 mcg orally once daily; increase by 5 mcg every 2-4 weeks based on thyroid function and clinical response. Maintenance: 25-50 mcg once daily. Weight-based: 1.6-2.6 mcg/kg/day.
Neonates: 10-15 mcg/kg/day orally. Infants: 5-10 mcg/kg/day. Children: 2-5 mcg/kg/day. Adjust based on T4 levels.
Start with lower initial dose of 12.5-25 mcg orally once daily; titrate slowly (increase by 12.5 mcg every 2-4 weeks) due to increased sensitivity and higher risk of cardiac complications. Monitor TSH closely.
Start at 25 mcg/day orally, titrate slowly (every 4-6 weeks) due to increased sensitivity and risk of cardiac adverse effects.
Not approved for weight loss; serious cardiovascular toxicity or death may occur, especially when used with sympathomimetic amines.
None specified in FDA labeling.
Cardiovascular adverse effects (angina, arrhythmias, hypertension, myocardial infarction),Thyrotoxicosis from excessive dosing,May increase anticoagulant effect of warfarin,May reduce glycemic control in diabetes,Bone demineralization with prolonged use
Cardiac toxicity: Increased risk of arrhythmias, angina, and myocardial infarction, especially in patients with pre-existing cardiovascular disease.,Hyperthyroidism: Can induce thyrotoxicosis if dose is too high or in patients with iodine deficiency.,Drug interactions: Enhances effect of oral anticoagulants (reduce warfarin dose); decreases effect of antidiabetic medications; alters response to digitalis.,Use in pregnancy: Category X – contraindicated due to teratogenic effects.
Untreated thyrotoxicosis,Acute myocardial infarction,Uncorrected adrenal insufficiency
Absolute: Euthyroid patients with pre-existing cardiovascular disease (e.g., recent MI, unstable angina, significant arrhythmias).,Absolute: Thyrotoxicosis or iodine deficiency.,Absolute: Pregnancy (Category X).,Relative: Renal or hepatic impairment; concomitant use of anticoagulants (requires close monitoring).
High-fiber foods, walnuts, soybean flour, and cottonseed meal may reduce absorption. Avoid excessive intake of iodine-rich foods (e.g., kelp, seaweed). Maintain consistent dietary habits for stable drug absorption.
High-fiber foods (e.g., bran, whole grains) may reduce absorption; take levothyroxine separately. Soy-containing products (e.g., tofu, soy milk) and grapefruit juice can alter absorption. Consume these at least 4 hours apart from dosing. Avoid taking with walnuts, cottonseed meal, or concentrated iron-rich foods.
Pregnancy category A. Thyroid hormones do not readily cross the placenta in early pregnancy; insufficient maternal thyroid hormone may cause fetal neurodevelopmental deficits. In first trimester, untreated maternal hypothyroidism linked to miscarriage and fetal anomalies; replacement therapy reduces risk. Second and third trimesters: maternal hypothyroidism associated with preterm birth, low birth weight, and impaired cognitive development; adequate dosing is critical. No evidence of teratogenicity at therapeutic doses.
CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of congenital defects; second and third trimester exposure may impair fetal thyroid function and development. Risk cannot be excluded.
Liothyronine (T3) is excreted into human breast milk in low concentrations; M/P ratio not established. Exogenous T3 may suppress endogenous maternal thyroid function. Benefits of breastfeeding generally outweigh minimal risk; infant thyroid function should be monitored if mother requires high doses. Use with caution.
Excretion into human milk is unknown. Due to potential for serious adverse effects in nursing infants, including interference with thyroid function, breastfeeding is contraindicated. M/P ratio not determined.
Pregnancy increases T3 clearance and decreases serum T3 levels. Dose requirements may increase by 30–50% compared to prepregnancy baseline. Frequent monitoring of free T3 and TSH is required; adjust dose to maintain free T3 in the upper normal range and TSH within trimester-specific targets. Dose adjustments should be made in increments of 5–12.5 mcg daily. Postpartum, dose usually returns to prepregnancy levels.
Pregnancy increases thyroid hormone requirements. Dextrothyroxine is not recommended due to lack of safety data. If used, dose may need increase based on TSH monitoring. Hyperthyroid effects may necessitate dose reduction. Not a standard therapy; levothyroxine is preferred.
Initiate at low doses (5-12.5 mcg/day) in elderly or cardiac patients; increase gradually every 1-2 weeks. Monitor TSH, T3, and T4 levels; T3 therapy can cause rapid swings in thyroid hormone levels. Use with caution in adrenal insufficiency, coronary artery disease, or diabetes insipidus. May increase warfarin sensitivity; reduce anticoagulant dose. Discontinue 2-4 weeks before thyroid uptake scans.
CHOLOXIN (sodium levothyroxine) is a synthetic T4 thyroid hormone. Monitor TSH levels 6-8 weeks after dose changes; target TSH 0.5-2.5 m IU/L for most adults. Administer on empty stomach, 30-60 minutes before breakfast, with water. Avoid concurrent calcium, iron, or antacids within 4 hours. Dose adjustments needed in pregnancy, with T4 dose increase by 30-50% typically. Check for drug interactions with amiodarone, oral contraceptives, and tyrosine kinase inhibitors.
Take exactly as prescribed; do not change dose without consulting your doctor.,Take on an empty stomach, at least 30 minutes before food or other medications.,Notify your doctor if you experience chest pain, rapid heartbeat, nervousness, or excessive sweating.,Do not stop suddenly; abrupt withdrawal can cause hypothyroid symptoms.,Inform all healthcare providers you are taking this medication.,May increase sensitivity to blood thinners; report signs of bleeding.
Take levothyroxine on an empty stomach, at least 30-60 minutes before breakfast.,Take with a full glass of water, not with other beverages.,Do not take within 4 hours of calcium or iron supplements, antacids, or sucralfate.,Consistency is key: take the same brand and dose daily; do not switch brands without consulting your provider.,Report symptoms of hyperthyroidism (palpitations, anxiety, weight loss) or hypothyroidism (fatigue, cold intolerance, constipation) promptly.,Do not stop or change dose without talking to your doctor; lab monitoring is required.,If you miss a dose, take it as soon as remembered, but skip if near next dose; do not double.,Inform all healthcare providers you are taking this medication, especially before surgery or starting new meds.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CYTOMEL vs CHOLOXIN, answered by our medical review team.
CYTOMEL is a Thyroid Hormone that works by Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.. CHOLOXIN is a Thyroid Hormone Analog that works by Choloxin (dextrothyroxine sodium) is a synthetic isomer of thyroxine that reduces serum cholesterol levels by increasing hepatic cholesterol catabolism and excretion, likely through enhanced LDL receptor activity and increased conversion of cholesterol to bile acids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CYTOMEL and CHOLOXIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CYTOMEL is: Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.. The standard adult dose of CHOLOXIN is: 50-250 mcg/kg orally once daily, adjusted to maintain T4 within normal range.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CYTOMEL and CHOLOXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CYTOMEL is classified as Category C. Pregnancy category A. Thyroid hormones do not readily cross the placenta in early pregnancy; insufficient maternal thyroid hormone may cause fetal neurodevelopmental deficits. In f. CHOLOXIN is classified as Category C. CHOLOXIN (dextrothyroxine) is not recommended during pregnancy. In animal studies, high doses caused fetal resorptions and anomalies. First trimester exposure may increase risk of . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.